60
Participants
Start Date
August 15, 2019
Primary Completion Date
March 14, 2022
Study Completion Date
March 14, 2022
Venetoclax
Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
Azacitidine
The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
Decitabine
The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
Prisma Health Cancer Inst - Eastside /ID# 211466, Greenville
Fort Wayne Medical Oncology /ID# 223523, Fort Wayne
Minnesota Oncology Hematology, PA /ID# 212837, Minneapolis
Texas Oncology - Medical City Dallas /ID# 211503, Dallas
Texas Oncology - Northeast Texas /ID# 213908, Tyler
Texas Transplant Institute /ID# 213311, San Antonio
Texas Oncology - Austin Midtown /ID# 212780, Austin
Rocky Mountain Cancer Centers /ID# 211508, Lone Tree
Colorado Blood Cancer Institute /ID# 212800, Denver
Arizona Oncology Associates, PC-HOPE /ID# 211509, Tempe
Oncology Hematology Care, Inc. /ID# 212779, Cincinnati
Willamette Valley Cancer Institute and Research Center /ID# 211504, Eugene
Charleston Oncology, P.A. /ID# 211471, Charleston
Tennessee Oncology - Chattanooga / McCallie /ID# 212717, Chattanooga
Tennessee Oncology-Nashville Centennial /ID# 210944, Nashville
Texas Oncology - San Antonio Medical Center /ID# 211510, San Antonio
Lead Sponsor
AbbVie
INDUSTRY